---
schema_version: "secwatch.filing_event.v1"
accession: "0000875320-26-000264"
form_type: "8-K"
ticker: "VRTX"
cik: "0000875320"
company_name: "VERTEX PHARMACEUTICALS INC / MA"
filed_at: "2026-09-01T20:25:14+00:00"
generated_at: "2026-09-01T20:26:16.161565+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vertex names Jonathan Poole CFO effective Jan 1, 2027; Wagner stays COO

## Summary
- Jonathan Poole, 51, appointed EVP & CFO effective Jan 1, 2027; was SVP Finance since March 2020.
- Charles Wagner ceases as CFO on that date but remains EVP & COO.
- Poole receives $750,000 base salary and 90% target bonus; severance equals 100% of base plus target bonus.
- Change-of-control agreement provides 100% base/target bonus, pro-rated bonus, and full equity vesting on qualifying termination.
- Poole previously CFO at Evelo Biosciences (2018-2020) and Genocea Biosciences (2014-2018).

## SEC filing metadata
- accession: 0000875320-26-000264
- form_type: 8-K
- ticker: VRTX
- cik: 0000875320
- company_name: VERTEX PHARMACEUTICALS INC / MA
- filed_at: 2026-09-01T20:25:14+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875320/000087532026000264/0000875320-26-000264-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875320/000087532026000264/vrtx-20260827.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000875320-26-000264
- JSON: https://secwatch.observer/filing/0000875320-26-000264.json
- Plain text: https://secwatch.observer/filing/0000875320-26-000264.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.